Rifampin
Rifadin IV
Rifamycin Antibacterial
NADAC/unit
$0.6253
Active Shortage
Tier 1: 59.3%
PA Req: 0.6%
7 Manufacturers
11 ANDAs
vs. brand Rifadin IV: Generic saves up to 94% per unit
Active Shortages
2021-12-22 On allocation, Lupin Pharmaceuticals, Inc.
2021-12-22 Discontinuation of the manufacture of the drug., Epic Pharma, LLC
2021-12-22 On allocation, Lupin Pharmaceuticals, Inc.
2021-12-22 Shortage reported, Epic Pharma, LLC
2021-12-22 On allocation, Lupin Pharmaceuticals, Inc.
Market Intelligence
2024-02-07 Class II Recall: Lupin Pharmaceuticals Inc.
2024-02-07 Class II Recall: Amerisource Health Services LLC
2024-02-07 Class II Recall: Lupin Pharmaceuticals Inc.
2023-01-25 Class II Recall: Amerisource Health Services LLC
2023-01-18 Class II Recall: Lupin Pharmaceuticals Inc.
Generic Manufacturers
CHARTWELL MOLECULAR HOLDINGS LLCEPIC PHARMA LLCFRESENIUS KABI USA LLCHIKMA PHARMACEUTICALSHIKMA PHARMACEUTICALS USA INCLUPIN PHARMACEUTICALS INCMYLAN LABORATORIES LTDOXFORD PHARMACEUTICALS LLCSANOFI AVENTIS US LLC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.